Literature DB >> 15653175

Immunochemical crossreactivity of antibodies specific for "advanced glycation endproducts" with "advanced lipoxidation endproducts".

Torsten Richter1, Gerald Münch, Hans-Joachim Lüth, Thomas Arendt, Rosemarie Kientsch-Engel, Peter Stahl, Dörte Fengler, Björn Kuhla.   

Abstract

Antibodies against advanced glycation endproducts (AGEs) are used for their immunohistological localization in tissues, for example in Alzheimer's disease (AD) or diabetes. Many monoclonal and polyclonal antibodies have been used, and their specificity is unknown in most cases. Increased radical production, leading to the formation of lipid-derived reactive carbonyl species, such as malondialdehyde (MDA), acrolein, and glyoxal, is a characteristic aspect of age-related diseases like Alzheimer's disease or diabetic polyneuropathy. These reactive carbonyl species are able to modify proteins, resulting in AGE related structures, termed "advanced lipoxidation products" (ALEs). In this study, the monoclonal carboxymethyllysine-specific antibody 4G9 and the polyclonal AGE-antibody K2189 were tested for their immunoreactivity towards these carbonyl-derived protein modifications. To investigate which carbonyl-modified amino acid side chains are specifically recognized by these antibodies, peptide membranes were incubated with glyoxal, MDA and acrolein. As model proteins, microtubuli associated protein tau (MAP-tau), beta-amyloid, human serum albumin and chicken egg albumin were incubated likewise. It was found that both antibodies detected reaction products of these carbonyl compounds on lysine- and arginine residues and for the protein modification, it was found that some epitopes might not be detected. In conclusion, AGE-antibodies might not only detect sugar-derived AGEs but also structures derived from lipid peroxidation products (serving as markers of oxidative stress).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653175     DOI: 10.1016/j.neurobiolaging.2004.04.009

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  7 in total

1.  Identification of AGE-modified proteins in SH-SY5Y and OLN-93 cells.

Authors:  André K Langer; H Fai Poon; Gerald Münch; Bert C Lynn; Thomas Arendt; D Allan Butterfield
Journal:  Neurotox Res       Date:  2006-06       Impact factor: 3.911

Review 2.  Endothelial Cell Metabolism.

Authors:  Guy Eelen; Pauline de Zeeuw; Lucas Treps; Ulrike Harjes; Brian W Wong; Peter Carmeliet
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

Review 3.  Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines.

Authors:  Matthew J Sharman; Giuseppe Verdile; Shanmugam Kirubakaran; Cristina Parenti; Ahilya Singh; Georgina Watt; Tim Karl; Dennis Chang; Chun Guang Li; Gerald Münch
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

Review 4.  Lipids and proteins--major targets of oxidative modifications in abiotic stressed plants.

Authors:  Naser A Anjum; Adriano Sofo; Antonio Scopa; Aryadeep Roychoudhury; Sarvajeet S Gill; Muhammad Iqbal; Alexander S Lukatkin; Eduarda Pereira; Armando C Duarte; Iqbal Ahmad
Journal:  Environ Sci Pollut Res Int       Date:  2014-12-05       Impact factor: 4.223

Review 5.  Site-specific oxidation of apolipoprotein A-I impairs cholesterol export by ABCA1, a key cardioprotective function of HDL.

Authors:  Baohai Shao
Journal:  Biochim Biophys Acta       Date:  2011-12-10

Review 6.  Oxidative Stress in Alzheimer's Disease: Should We Keep Trying Antioxidant Therapies?

Authors:  Michelli Erica Souza Ferreira; Amanda Soares de Vasconcelos; Thyago da Costa Vilhena; Thiago Leite da Silva; Aline da Silva Barbosa; Antonio Rafael Quadros Gomes; Maria Fani Dolabela; Sandro Percário
Journal:  Cell Mol Neurobiol       Date:  2015-01-24       Impact factor: 5.046

7.  Cell cycle related signaling in Neuro2a cells proceeds via the receptor for advanced glycation end products.

Authors:  A Schmidt; B Kuhla; K Bigl; G Münch; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2007-06-14       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.